Chapter 48: Immunosuppressant Drugs

The major drug classes are presented systematically: glucocorticoids that broadly suppress immune function; calcineurin inhibitors including cyclosporine and tacrolimus that block T-cell activation by preventing cytokine release; mTOR inhibitors such as sirolimus and everolimus that interrupt cell proliferation signaling; antimetabolites like azathioprine and mycophenolate that interfere with nucleotide synthesis in lymphocytes; and monoclonal antibodies including basiliximab that target specific immune mediators. Each medication is detailed with its mechanism of action, clinical indications across different transplant types and autoimmune conditions, dosing considerations, and serious adverse effects including nephrotoxicity, hepatotoxicity, infection risk, and malignancy. The chapter emphasizes the critical balance between adequate immunosuppression to prevent rejection and minimizing infection and cancer risk inherent to these therapies. Nursing responsibilities encompass comprehensive baseline assessments of renal and hepatic function, ongoing monitoring of drug levels and laboratory markers, identification of significant drug interactions involving cytochrome P450 interactions and dietary components like grapefruit juice, and prevention of medication errors due to narrow therapeutic windows. Implementation guidance covers safe administration techniques, patient education about lifelong medication adherence, contraindications to live vaccines, early recognition of infection signs, and management of specific side effects. The chapter also addresses the broader healthcare context including ethical considerations in organ allocation and transplantation, socioeconomic barriers to accessing immunosuppressive therapy, and the psychosocial needs of transplant recipients requiring multidisciplinary nursing support.